Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapanisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 15/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 9/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 9/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 9/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 9/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 8/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 8/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 8/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.82 |
| ▸ | STK16 | O75716 | 1/20 | 0.82 |
| ▸ | STK10 | O94804 | 1/20 | 0.82 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.82 |
| ▸ | RET | P07949 | 1/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.82 |
| ▸ | PRKCA | P17252 | 1/20 | 0.82 |
| ▸ | DCK | P27707 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapanisertib SCHEMBL29351459 | 1.00 | MTOR (1.00) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL7901532 | 0.92 | MTOR (1.00) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL16546279 | 0.91 | MTOR (0.84) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL16117323 | 0.90 | BMPR1B (1.00) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL15497301 | 0.89 | MTOR (0.79) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL7895680 | 0.89 | MTOR (0.79) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL15497291 | 0.89 | MTOR (0.79) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| Sapanisertib SCHEMBL7895668 | 0.87 | MTOR (0.77) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL19299482 | 0.87 | MTOR (0.77) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL22494446 | 0.87 | MTOR (1.00) | MTORPIK3CARICTORRPTORMAPKAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO., LTD. (KR) | 2021-06-24 | — | — | US | claimed |
| EP-3266455-B1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING MTOR INHIBITOR | KOREA ADVANCED INST SCI & TECH (KR) | 2020-12-30 | — | — | EP | claimed |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2020-12-17 | — | — | US | claimed |
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | claimed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4706773-A2 | HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010051043-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051042-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | MTOR 995/4885PIK3CA 322/4885RICTOR 3267/4885 |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | CD47, IFNG, TLR9 | MTOR 4297/4885PIK3CA 2448/4885RICTOR 4153/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | MTOR 2/4885PIK3CA 4/4885RICTOR 130/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MTOR 15/4885PIK3CA 52/4885RICTOR 149/4885 |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | CD2, CD22, KLRK1 | MTOR 3931/4885PIK3CA 1947/4885RICTOR 4578/4885 |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 358/4885RICTOR 4/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | MTOR 2/4885PIK3CA 4/4885RICTOR 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.